CRISPR Therapeutics Posts $116M CASGEVY Revenue, Threefold Patient Initiations Growth
CRISPR Therapeutics reported encouraging clinical data for its allogeneic CAR-T candidate zugocabtagene geleucel in both autoimmune and oncology indications. CASGEVY generated $116 million in 2025 revenue with patient initiations increasing nearly three-fold year-over-year.
1. Business Update Highlights
CRISPR Therapeutics provided a business update detailing encouraging clinical data from its allogeneic CAR-T candidate, zugocabtagene geleucel, in both autoimmune disease and oncology indications.
2. CASGEVY Revenue and Uptake
The company reported $116 million in full-year 2025 CASGEVY revenue, with patient initiations increasing nearly three-fold year-over-year and expanding its global footprint.
3. Allogeneic CAR-T Platform Development
CRISPR is advancing its off-the-shelf CAR-T approach aimed at enabling allogeneic cell therapies without patient-specific manufacturing bottlenecks.
4. Pipeline and In Vivo Editing
The update also highlighted progress across preclinical in vivo liver editing programs, underscoring CRISPR’s broader gene-editing and oncology strategy.